Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Cecelia R. Valrie, PhD
Researcher Associate Professor
Virginia Commonwealth University
907 Floyd Ave
Richmond, Virginia, United States
Dr. Cecelia Valrie is a developmental-health psychologist. Her research primarily focuses on adjustment in children and adolescents with sickle cell disease (SCD) and their families, focusing on pain, sleep, academic functioning, and health-related outcomes. She is currently conducting research on:
(1) the temporal relationship between sleep and pain in children and adolescents with SCD, and
(2) the influence of sleep, pain, and family functioning on academic and health-related outcomes in children and adolescents with SCD.
Dr. Valrie also has research interests in the transition to adulthood for pediatric populations and the influence of socio-cultural factors on pediatric health outcomes. She is currently developing projects focusing on building resilience in children, adolescents, and young adults with a chronic illness to improve their long-term health and career outcomes, and understanding the influences of parental and family factors on preparation for transitioning to adulthood in pediatric population.
Representative Publications:
Experiences of Pediatric Patients With Sickle Cell Disease in Rural Emergency Departments
Risk and resilience factors for grade retention in youth with sickle cell disease
Optimism predicting daily pain medication use in adolescents with sickle cell disease
Related Content
-
Susan Claster, MDDr. Claster graduated from the Universit...
-
Rita Paschal, MDDr. Paschal is Associate Professor of me...
-
Secondhand smoke is associated with more frequent hospitalizations in children with sickle cell diseaseTobacco smoke exposure has been associat...
-
University of Illinois HospitalThe Sickle Cell Program at UI Health is ...
-
The Sickle Cell Care Coordination InitiativeThe Sickle Cell Care Coordination Initia...
-
Perioperative considerations for patients with sickle cell disease: a narrative reviewPURPOSE: Approximately 200,000 individua...
-
GlycoMimetics Announces Pricing of Public Offering of Common StockGlycoMimetics, Inc. (NASDAQ: GLYC), a cl...